NCT Number: NCT04399174
Placental Vasculature for Prediction of Recurrent Fetal Growth Restriction
: In this Prospective longitudinal observational study, two hundred pregnant women with singleton pregnancy from 11 up to 13 weeks with history of intrauterine growth restriction in a previous pregnancy underwent ultrasound assessment of gestational age , ultrasound assessment of uterine artery pulsatility index, placental volume by 3D ultrasound and placental vascularization by 3D power Doppler (3DPD).
Looking for future studies?
Notify MeKey information
About this study
This Prospective longitudinal observational study was conducted at Benha University hospital starting from December 2016 to May 2019 after approval of faculty Research Ethics Board. Two hundred pregnant women with history of IUGR in previous pregnancy were recruited for the study after full explanation of the method, aim of work and obtaining consent. Inclusion criteria: singleton pregnancy from 11 up to 13 weeks. History of intrauterine growth restriction in previous pregnancy Exclusion criteria: Multiple pregnancies, Smoking women, and pre-existing medical disorders which may affect fetal growth e.g. hypertension, diabetes mellitus, thyroid dysfunction or renal impairment. Ultrasound evidence of congenital anomalies.
All women underwent ultrasound study which was performed by a member of ultra-sound unit (Volsun 730 pro V; G.E medical system), for assessment of: Gestational age confirmed by crown-rump length assessment, Uterine artery pulsatility index (angle of insonation is<50°, the sampling gate set at 2mm), 3D ultrasound assessment of Placental volume, 3DPD for assessment of placental vascularization. The examination was done with the patient in lithotomy position with slight left lateral tilting to avoid supine hypotension.
After visualization of the placental vasculature, 3D static power Doppler scanning was performed. After scanning the region of interest, placental volume was measured using the VOCAL rotational technique and VOCAL software (3D Sono View, GE Medical Systems, Milwaukee, WI, USA). After completing a full rotation, another analysis was performed using VOCAL Software (3D Sono View, GE Medical Systems, Milwaukee, WI, USA), which automatically calculates placental volume, vascularization index (VI), flow index (FI) and vascularization flow index(VFI). Low dose aspirin 75mg was described for all cases with the beginning of 2nd trimester.
All cases were having a second (between 20 to 24 weeks) and a third ultrasound assessment for exclusion of congenital malformation and assessment of fetal growth parameter and identification of IUGR cases (according to fetal growth curves). (Nicolaides KH et al., 2018). In order to avoid including healthy, yet constitutionally small for gestational age fetuses to the IUGR group, patients' data were included in the study only in cases of IUGR diagnosis confirmed after delivery.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- singleton pregnancy from 11 up to 13 weeks.
- History of intrauterine growth restriction in previous pregnancy
Exclusion criteria
• Multiple pregnancies,
- Smoking women, and
- pre-existing medical disorders which may affect fetal growth e.g. hypertension, diabetes mellitus, thyroid dysfunction or renal impairment.
- Ultrasound evidence of congenital anomalies.
Treatment and study plan
Primary outcomes
-
placental volume
Time frame: 11-13 week
Assessment of placental volume.
-
vascularization index (VI)
Time frame: 11-13 week
expressed as percentage, measures the number of colour voxels in the studied volume, representing the blood vessels within the tissue
-
uterine doppler
Time frame: 11-13 week
uterine artery pulsatility index
-
flow index (FI)
Time frame: 11-13 week
the average colour value of all colour voxels, representing average colour intensity.
-
vascularization flow index (VFI)
Time frame: 11-13 week
the average colour value of all grey and colour voxels, which represents both blood flow and vascularization
Sponsors and collaborators
Lead sponsor
Benha University
Other
Registry information
Official study title
3DPD of the Placenta in Fetal Growth Restriction
Important dates
- Study start
- 2016
- Primary completion
- 2019
- Study completion
- 2020
- First posted
- May 22, 2020
- Registry last updated
- May 22, 2020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Lung Ultrasound in Critically Ill Obstetrics and Gynecological Patients
NCT06728709
Gynecologic Cancer, Lung Diseases
Cairo, Cairo Governorate, Egypt
View Trial DetailsNoninvasive Monitoring of Uterine Activity and Fetal Heart Rate
NCT05782296
Fetal Heart Rate or Rhythm Abnormality Affecting Newborn During Labor, Obstetric Complication
Hoffman Estates, Illinois, United States
View Trial DetailsIntra-abdominal Umbilical Vein Aneurysm
NCT03653884
Obstetric Complication
Cergy-Pontoise, France
View Trial DetailsEffect of COVID-19 Infection on Obstertric Complications and Maternal Outcomes
NCT06557694
COVID-19, Coronaviridae Infections
Tanta, El-Gharbia, Egypt
View Trial Details